Increasing awareness Update on CVIDs

Helen Chapel University of Oxford helen.chapel@ndm.ox.ac.uk



Contents

> Awareness

- How common are PADs ?
- Why is diagnosis delayed ?
- Common variable immune deficiency disorders i.e. CVIDs
 - Who is affected and when ?
 - How do patients present ?
 - Single gene or polygenic disease ?
 - Management, including SCIg and home therapies

Why Awareness?

- > EU conference on PIDs in June 2006
- Funded by EU Commission
- To produce a statement to be adopted by EU as a Consensus statement on these rare diseases
- > To tell National Governments to provide funds for PID services
- > 2007/14 is 7th EU Framework in which PIDs are a priority

Prevalence (in adults)

Diseases:	Per 10 ⁵ population
Rheumatoid arthritis	1,000
Type I diabetes	200
Multiple sclerosis	60
Systemic lupus erythematosus	5 0
"CVIDs"	4
Scleroderma	

Diagnostic delay - significant delay from onset of symptoms to diagnosis

UK 1989 Mean: 4 years in children 6 years in adults

Blore & Haeney

Manchester

UK National audit 1995 Mean 5 years > Range [3.56 - 9.4 yrs] > Varied with locality > On type of antibody deficiency > Mean 7.3 years for CVDS Spickett, Askew & Chapel 2005

Mean: 4.4 years Median: 2 years

> Seymour, Miles & Haeney

Evidence for diagnostic delay (data from Spickett, Askew & Chapel 1995)



Reasons for delay

- Patients may be seen by other specialists before coming to immunologists
 - Which specialties in particular ?
 - How can referral for diagnosis and treatment be speeded up ?
- General public awareness is low
 - Encourage patient organizations to ensure general awareness, especially schools
 - Education for physicians in primary care as well as hospital specialties
 - Healthcare providers

Public awareness

Potential patients - Patient organisations

- Recurrent / unexplained infections
- Loss of schooling/ time off work / visits to doctors
- Unexplained granuloma, lymphoid infiltrations, atypical "lymphoma", autoimmune cytopenias, splenomegaly, etc.
- Healthcare providers Hospital managers
 Hospital laboratories and clinical services

Government agencies - EU Commission

- Provision of therapies, resources for diagnostic tests/centres
- Comparison with other EU countries

Primary care doctors - from Rasa Duobiene



- 1. Six or more new documented ear infections requiring antibiotics < 1 year
- Two or more unexplained documented sinus infections requiring antibiotics < 1 year
- 3. Two or more months on antibiotics without clinical improvement /resolution
- 4. Two episodes of pneumonia in any 2 year period in a non-smoker
- 5 Failure to thrive in an infant without an obvious explanation Investigations for PID should be first line, as for sweat test and TTG / endomysial antibodies
- 6. Recurrent deep skin or organ abscesses in anatomical different sites
- 7. Persistent unexplained oral thrush or on skin after one year of age
- 8. Need for intravenous antibiotics to clear infections more than twice in life-time
- 9. Two or more deep seated infections in different anatomical sites in life-time
- 10. Family history of recurrent / severe/ persistent / unusual infections

NEONATAL MEDICINE

Malcolm I. Levene, David I. Tudehope & M. John Thearle THIRD EDITION



pneumonia 101 Russel-Silver syndrome 248

sail sign 103 salbutamol 175 saliva 27 Salmonella 64,75 Sandifer syndrome 57 scalded skin syndrome 276-7 scalp, fetal pH 11 scalp electrode mon ng 35

scaphocephaly 25 sciatic nerve injury 40 incia 247 8

scrotum 30 seborrhoeic dermatitis 277-8 Seckel's bird head 248 seizures 21, 230-4 sepsis, hypocalcaemia 171 septicaemia 71-2, 170 exchange transfusion 316

serratia 71,91

pneumonia 101 sex-linked disorders 159

shock 205 short bowel syndrome 270 shoulder dystocia 169 sick infants

social worker 301 sodium conservation 25 dietary 46 metabolic disord sodium bicarbonat 201 soft tissue injuries soya bean milks 60 special care 283-4 see also intensive specific gravity, uri spina bifida 218, 2 cystica 220, 221 management 22 occulta 219, 220 spinal cord injury spinal muscle atrop spinnaker sign 10. spiramycin 66, 33 spironolactone 19 spleen 29 injuries 41 splints, congenital i 247 Staphylococcus 70 pneumonia 101 Staphylococcus au

73.74

Lack of awareness is no surprise..... if doctors don't know

Taeusch - Avery



Pocket Companion to Accompany

Avery's Diseases of the

Newborn 7th Edition



Salmonella, in infectious diarrhea, 199 Salt wasting, virilization with hyperplasia, 523 Scalp, hemorrhagic edema of. 424 Screening program(s), neonatal, 106t. for alpha₁-antitrypsin de-

ficiency, 118 for biotinidase deficiency 119_113

abnormalities of, for neur alastoma, 117 524-531. See also for pheny onuria specific disorder, e. 106-107 urner oun for sickle cell disease. 113-114 Sexually transmitted of umbilical cord blood, disease(s). See also specific disease, e.g., for maternal metabolic disorders, 119-Suphilis. ophthalmia neonatorum as-120 Seizure(s), 431-434 sociated with, 206-208 Shigellosis, 200 hypocalcemic crisis with, treatment of, 514 ampicillin for, 201 Short-chain acyl-CoA risk of, 431 treatment of, maintenance dehydrogenase (SCAD) schedules in, 433-434 deficiency, 100 phases in, 433 types of, 431-432 Selenium deficiency, in bronchopulmonary dysplasia, 289 Sepsis, associated with bilirubin overproduction. 476 Escherichia coli, 193 in GALT deficiency, 77 neonatal. See Septicemia. Septal defect(s). atrioventricular, 376-379 ventricular, 372-376 ntic arthritis 202 00

Shunt (shunting), left-to-right, in atrioventricular septal defects, 377 in cardiac disorders, 312-313 through ductus arterio sus, 300, 301 right-to-left, causing differential cyanosis, 314 in aortic stenosis, 367 in cardiac disorders, pro pensity for, 320 in Ebstein anomaly, 351-352 in pulmonary stenosis

Sexual differentiation.

uon of 525

RICHARD E. BEHRMAN

NELSON Essentials of PEDIATRICS

Clinics presented with infections

(data from Spickett, Askew & Chapel. UK Audit of PIDs)

INFECTION	PERCENTAGE OF PATIENTS	DEPARTMENTS VISITED
Recurrent chest infections	67.5	Respiratory
Recurrent sinus infections	23.3	ENT
Infections in the gastrointestinal tract	10.8	Gastroenterology
Cutaneous infections	7.9	Dermatology
Bacterial meningitis	4.4	Neurology
Septic arthritis	1.2	Rheumatology
Recurrent conjunctivitis	1.4	Ophthalmic

> 60% of diagnoses were NOT made in first three hospital visits, despite long histories & multiple depts.

Prevalence of Medical Stat Patients Across Euro



Age of onset of symptoms in CVIDs as percentages in each

country



Contents

> Awareness

- How common are PADs ?
- Diagnosis delay
- Who is affected and when ?
- Common variable immune deficiency disorders i.e. CVIDs
 - How do patients present ?
 - Single gene or polygenic disease ?
 - Management, including SCIg and home therapies

Criteria for diagnosis:

- Agreed by ESID (<u>www.esid.org</u>)
- For clinical help & studies/registers etc
- Definite = 98% probability that same diagnosis in 20 years;gene mutation & clinical features, so not applicable to CVIDs
- Probable = 85% probability that same diagnosis in 20 years; clinical & lab features as no known single gene defect applicable to CVIDs



Common Variable Immune Deficiency Disorders [CVIDs]

Probable: male/female patient with all of:

- > Aged > 4 years
- Serum IgG and IgA (probably not IgM) more than 2 SD below mean for age
- > Poor response to all vaccines

 Causes of secondary antibody deficiencies excluded (eg lymphoma, medications)

Presenting Infections

PERCENTAGE PATIENTS INFECTION Recurrent chest infections 67.5 **Recurrent sinus infections** 23.3 10.8 **Gastrointestinal tract Cutaneous infections** 7.9 **Bacterial meningitis** <u>4</u> <u>4</u> **Septic arthritis** 1.2**Recurrent conjunctivitis** 1.4

But infections are not everything....

Complicatons - Autoimmunity

Autoimmunity

- > Arthropathy 6%
 > IDDM 4.5%
- > Hypothryoid 4.5%
- Pern. Anaemia 5%
- > Vitiligo 4.5%
 > subtotal 24.5%

Cytopenias	
	<mark>7%</mark>
> AHA	4.5%
> Neutropenia	<mark>3%</mark>
> subtotal	14.5%

Complications: Lymphoid infiltration

10%

Others

- **6%** > Atrophic gastritis 5%
- > Enteropathy

pneumonitis

- > Granuloma 12%
- > Idiopathic hepatomegaly

- > Iron deficiency
- Fat soluble vitamin deficiencies
- > Gastric cancer
- > NHL
- 4% > Lymphadenopathy 10% > Splenomegaly 30% > Lymphoid interstitial
- > Bronchiectasis 30%

NONE 28%

Complications: Lymphoid infiltration

5%

Others

- > Atrophic gastritis
- > Enteropathy
- > Granuloma
- > Idiopathic hepatomegaly

- Iron deficiency
- 6% > Fat soluble vitamin deficiencies
- 5 70 > Gastric cancer

 12% > NHL

Bronchiectasis 30%

4%

- > Lymphadenopathy 10%
- Splenomegaly 30%
- > Lymphoid interstitial pneumonitis 10%

NONE 28%

Granulomatous disease in CVID

- > 42% patients with lymphoproliferation
- > of which 12% had granuloma
- Samples contained noncaseating granulomata
- > Organ or tissue biopsy essential for confirmation & distinguish infection
- > Respond to corticosteroids usually
- > ? Infectious aetiology
- > ? diagnostic delay contributed to severity

ESID CVIDs Registry 2006

Cerebral granulomata

- Frontal lesion aged 10 yrs ? tumour
 21 yrs symptoms raised pressure, temporal lesion granuloma again at 40 yrs
- Panhypogamma lgG<1 g/l
- Few bacterial infections



Tongue & skin granulomata



QuickTime^{1w} and a TIFF (Uncompressed) decompressor are needed to see this picture.

23

Complications: Lymphoid infiltration

5%

Others

- > Atrophic gastritis
- Enteropathy
- > Granuloma
- > Idiopathic hepatomegaly

- Iron deficiency
- 6% > Fat soluble vitamin deficiencies
- **5**70 > Gastric cancer **12%** > NHL
 - **Bronchiectasis 30%**

<mark>4%</mark>

- > Lymphadenopathy 10%
- Splenomegaly 30%
- > Lymphoid interstitial pneumonitis 10%

NONE 28%

Complications: Lymphoid infiltration

5%

Others

- > Atrophic gastritis
- Enteropathy
- > Granuloma
- > Idiopathic hepatomegaly

- Iron deficiency
- 6% > Fat soluble vitamin deficiencies
- 5 % > Gastric cancer

 12% > NHL

Bronchiectasis 30%

4%

- > Lymphadenopathy 10%
- Splenomegaly 30%
- > Lymphoid interstitial pneumonitis 10%

NONE 28%

CVID lung syndrome – with SOB, fatigue & dry cough; CT ground glass areas

Needle core bx lung showing CD4 and CD8 proportions; few B cells (not shown) .No granuloma. **Diagnosis LIP**





Cyclosporin A + corticosteroids Davies et al Thorax. 2000²⁶

Bronchiectasis



Silent progression of bronchiectasis in a few patients even on Trough IgG > 8 g/L? related to: diagnostic delay • dose of lg type of CVID

Complications: Lymphoid infiltration

5%

Others

- > Atrophic gastritis
- Enteropathy
- > Granuloma
- > Idiopathic hepatomegaly

- Iron deficiency
- 6% > Fat soluble vitamin deficiencies
- 5 70 > Gastric cancer

 12% > NHL

Bronchiectasis 30%

4%

- > Lymphadenopathy 10%
- Splenomegaly 30%
- > Lymphoid interstitial pneumonitis 10%

NONE 28%

Enteropathy due to Giardia



- Giardiasis missed repeatedly
- Not found on stool microscopy
- Resistant to Metronidazole
- > "unexplained malabsorption
- > Needed TPN

CVID Enteropathy syndrome: Duodenum with focal intraepithelial T lymphocytosis Responded to Budesonide Beware fat soluble vitamin deficiencies A,D and E





Case History -enteropathy

Previously Night blindness - vitamin A deficiency on therapy Retinitis pigmentosa

<u>Now</u> ataxia & tremors low vitamin E = 2.75 mmol/L

CSF - normal

 MRI of the brain revealed extensive high signal change in the white matter
 Oral vitamin E (80mg/day) - asymptomatic+ MRI resolution

MRI diffuse high signal white matter changes in case pre-treatment (C) and improved after treatment (D).



Summary of clinical presentations in CVIDs > Childhood presentation - not always FFT

- Recurrent / severe infections e.g. rec. otitis media or 2 episodes pneumonia - not necessarily both
- Autoimmune disease e.g. ITP, AHA, thyroid failure
- Rarer lung, liver, GI features should alert suspicion

Contents

How common are PADs ? > Why is diagnosis delayed ? > Who is affected and when ? How do patients present ? Single gene or polygenic disease ? Management, including SCIg and home therapies

Positive family history: Unusual



European data

Not likely to be single genes involved

IUIS 2006

Diseas	e	B cell numbers	Serum Ig	Associated Features	Inheritance	Genetic Defects/presumed pathogenesis
2. Seve serum i with no cells	ere reduction in at least 2 mmunoglobulin isotypes rmal or low numbers of B					
a)	Common variable immunodeficiency disorders*	Normal or decreased	Decrease in IgG & IgA; IgM may be normal	May have autoimmune, lymphoproliferative and/or granulomatous disease	Variable	Unknown
b)	ICOS deficiency	Normal or decreased	Decrease in IgG & IgA; IgM may be normal	Recurrent bacterial infections	AR	Mutation in <i>ICOS</i>
c)	CD19 deficiency	Normal	Decrease in IgG & IgA; IgM may be normal	Recurrent bacterial infections	AR	Mutation in <i>CD19</i>
d)	TACI deficiency	Normal	Decrease in IgG & IgA; IgM may be normal	May have autoimmune or lymphoproliferative disease	AD or AR	Mutation in <i>TACI</i>
e)	BAFF receptor deficiency	Normal or decreased	Decrease in IgG & IgA; IgM normal	Recurrent bacterial infections	AR	Mutation in BAFFR

•This is a diagnosis of exclusion of other known primary antibody deficiencies. There are several different clinical phenotypes, probably representing distinguishable diseases with differing immunopathogeneses.

New Molecular Defects in CVID

TACI deficiency (Nat Genet August 2005)

Ulrich Salzer et al

BAFF receptor deficiency (2006)

Klaus Warnatz et al

CD19 deficiency (NEJM, 2006)

Jose-Luis Franco et al

ICOS deficiency (*Nat Immunol*, 2003)

Grimbacher et al.

? Polymorphisms, disease causing, disease modifying ?

Contents

> How common are PADs ? > Why is diagnosis delayed ? > Who is affected and when ? How do patients present ? Single gene or polygenic disease ? Management, including SCIg and home therapies

Subcutaneous lg therapy

 Easy to use
 Safe
 Efficacious as IVIg in infection prevention

J-Clin-Immunol. 2000



Efficacy of SCIg

- Cross over trial in UK & Sweden
- > 40 patients, 12 months of each
- > 4 withdrawals in each arm
- > Analysed for 9 months of each arm i.e. wash out
- > Patient preference equal most either
- > Adverse reactions mild & usually local

Chapel et al J-Clin-Immunol. 2000

IgG levels with shorter IVIg intervals



IgG levels with SCIg every 1-2 days





Route of Immunoglobulin therapy



My thanks to:

- Funding in Oxford from the 6th EU Framework EUROPOLICY, PiA Centre of Excellence Award PiA
- My colleagues in Immunology Drs Misbah, Lopez-Grandados and Lortan, Sisters Janet Burton and Nicky Brennan
- The Francouer foundation -Quebec ZLB-Behring



Numbers of B cells (%) : Variable

CVIDs vs Controls



Numbers of B cells (%) in groups

Immunoglobulin levels: Variable Immunoglobulin isotypes at presentation in 1,294 "CVID" patients Pan-European registry 1992 -2004

